Repligen (RGEN) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Ethic Inc. acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) in a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 3,054 shares of …

Twist Bioscience Corp., Cloudflare Inc., and Repligen Corporation were among the top contributors to performance. We believe Cloudflare's extensive network and expanding product portfolio position it to benefit from risi…

Repligen delivered revenue of $209 million in the third quarter. BioLife is expected to contribute $24 million in fourth-quarter revenue.…

WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and …

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of…

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript…

Repligen NASDAQ: RGEN reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and Analytics franchises …

The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, De…

Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.46 per share a year ago.…

Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife acquisition, which fast-tracks Repligen's leadership and offering in high-growth cell therapy market Ra…

Krilogy Financial LLC lowered its position in shares of Repligen Corporation (NASDAQ: RGEN) by 31.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund…

Repligen demonstrates 13% organic growth despite Filtration headwinds, with strong momentum in the Proteins and Process Analytics segments. Filtration's drag is temporary, with mid-single-digit growth expected in 2026 an…

WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026.…

On October 06, 2026, Repligen Corp (RGEN) shares experienced a notable decline of 7.7%, bringing the current price to $174.86. This movement comes amid a 52-wee…

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has complete…

On October 05, 2026, Repligen Corp (RGEN) shares rose 4.3%, bringing the current price to $189.50. The stock has experienced a 52-week range from a low of $100.…

BioLife Solutions NASDAQ: BLFS stockholders approved the company's merger agreement with Repligen Corporation at a special meeting held virtually on Oct. 5, 2026, clearing a key shareholder-vote requirement for the propo…

Repligen Corporation (NASDAQ: RGEN - Get Free Report) reached a new 52-week high on Wednesday. The stock traded as high as $188.95 and last traded at $186.9330, with a volume of 25119 shares traded. The stock had previou…

Tidal Investments LLC increased its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 75.2% during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commiss…

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (…

WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 22. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

